Clinical Trial Update: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing disease control and safety in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod; the study was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)
• Tysabri (Natalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: TERMINATED | Results posted: 2014-04-04